Scenarios that move MCK
McKesson Corporation Common Stock
Scenarios that move MCK: 25 analyses, 24 positive, 1 negative.
- · Opus Genetics receives FDA approval for presbyopia eye drop — ▲ · impact +8 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▲ · impact +25 · confidence medium · horizon weeks
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +9 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +22 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +26 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +25 · confidence low · horizon quarters
- · Hims & Hers faces securities fraud class action after FTC lawsuit — ▲ · impact +12 · confidence low · horizon quarters
- · Viatris to acquire Pacira for $1.65B in pain portfolio deal — ▲ · impact +25 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +18 · confidence low · horizon quarters
- · ◇ What if… Plague outbreak in Russia continues and spreads further — ▲ · impact +18 · confidence low · horizon weeks
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +12 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +8 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +8 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +20 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +47 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +8 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +10 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +12 · confidence low · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▲ · impact +6 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +36 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +8 · confidence low · horizon quarters
- · Tech stocks slide as dire AI warnings send Micron down 5% — ▲ · impact +24 · confidence low · horizon weeks
- · FDA approves Isembyld for spinal muscular atrophy treatment — ▲ · impact +30 · confidence low · horizon weeks
- · ◇ What if… Major Cyberattack Takes Down Two Largest US Health Insurance Claims Processors — ▼ · confidence low
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▲ · confidence low